| Net income |
578.63M |
| Continuing operations |
425.58M |
| Discontinued operations |
| Amortization of above and below market lease intangibles, net |
-1.39M |
| Stock-based compensation |
19.31M |
| Amortization of debt premiums, discounts and issuance costs, net |
15.6M |
| Straight-line rents |
| Interest accretion |
| Deferred rental revenues |
-1.03M |
| Equity income from unconsolidated joint ventures |
4.03M |
| Distributions of earnings from unconsolidated joint ventures |
5.92M |
| Gain upon consolidation of joint venture |
| Marketable securities gains, net |
| Gain upon settlement of loans receivable |
| Derivative (gains) losses, net |
| Impairment recoveries |
| Accounts receivable, net |
7.56M |
| Other assets |
-9.67M |
| Accounts payable and accrued liabilities |
40.67M |
| Net cash provided by operating activities |
998.63M |
| Cash used in the HCR ManorCare Acquisition, net of cash acquired |
| Cash used in the HCP Ventures II purchase, net of cash acquired |
-10.17M |
| Other acquisitions and development of real estate |
| Leasing costs and tenant and capital improvements |
| Purchase of an interest in and contributions to unconsolidated joint ventures |
| Distributions in excess of earnings from unconsolidated joint ventures |
14.46M |
| Proceeds from the sale of securities |
0 |
| Principal repayments on loans receivable |
221.18M |
| Investments in loans receivable |
| Increase in restricted cash |
4.46M |
| Net cash used in investing activities |
-314.16M |
| Repayment of term loan |
| Repayments of mortgage debt |
-249.54M |
| Issuance of senior unsecured notes |
0 |
| Debt issuance costs |
-1.06M |
| Net proceeds from the issuance of common stock and exercise of options |
| Dividends paid on common and preferred stock |
-806.24M |
| Sale (purchase) of noncontrolling interests |
4.79M |
| Distributions to noncontrolling interests |
-18.69M |
| Net cash provided by (used in) financing activities |
-897.33M |
| Net decrease in cash and cash equivalents |
-213.61M |
| Cash and cash equivalents, beginning of period |
346.5M |
| Cash and cash equivalents, end of period |
132.89M |
